Search
GZ-389988
go.drugbank.com/drugs/DB16056InvestigationalGZ-389988 is under investigation in clinical trial NCT02845271 (Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients
KYV-101
go.drugbank.com/drugs/DB23168InvestigationalKYV-101 is under investigation in clinical trial NCT06152172 (CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101).
Nifekalant
go.drugbank.com/drugs/DB16008InvestigationalNifekalant is under investigation in clinical trial NCT03855826 (Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection).
TC-6987
go.drugbank.com/drugs/DB14854InvestigationalTC-6987 is under investigation in clinical trial NCT01296087 (TC-6987 for the Treatment of Mild to Moderate Asthma).
Vantictumab
go.drugbank.com/drugs/DB12956InvestigationalVantictumab has been used in trials studying the treatment of Solid Tumors, Pancreatic Cancer, and Stage IV Pancreatic Cancer.
Rivabazumab pegol
go.drugbank.com/drugs/DB17788InvestigationalRivabazumab pegol is being investigated as a treatment of Pseudomonas aeruginosa lung infections in patients with cystic fibrosis.[A259457]
Synonyms: KB001-A (AN ANTI-PCRV PEGYLATED MONOCLONAL ANTIBODY FRAGMENT TO THE TYPE III SECRETION SYSTEM OF PSEUDOMONAS AERUGINOSA)E59
go.drugbank.com/drugs/DB18372ExperimentalE59 is a humanized IgG1 low affinity allergic reactivity inhibiting (LARI) monoclonal antibody. It was developed by Sixal Inc.
Coprelotamab
go.drugbank.com/drugs/DB16380InvestigationalCoprelotamab is under investigation in clinical trial NCT04170595 (Clinical Study of Recombinant Anti-her2 Humanized Monoclonal Antibody for Injection).
Toralizumab
go.drugbank.com/drugs/DB16384InvestigationalToralizumab is under investigation in clinical trial NCT03605927 (CD40-L Blockade for Prevention of Acute Graft-versus-host Disease).
Clesacostat
go.drugbank.com/drugs/DB18956InvestigationalClesacostat is under investigation in clinical trial NCT04321031 (Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)).